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Summary The metabolism of serotonin was studied in cancer patients of their first day of their first course of
chemotherapeutic drugs either with strongly or moderately emetogenic regimens. It was observed that strongly
emetogenic treatments induce greater increases in serotonin release than moderately emetogenic regimens.
High-dose cisplatinum (75 ± 5 or 83.8 ± 5 mg m-2) produced a marked increase in the plasma levels and in the
urinary excretion of 5-hydroxyindole acetic acid (5-HIAA). Neither platelet nor plasma (platelet-free plasma)
serotonin were significantly modified by high-dose cisplatinum. Dacarbazine (283 ±22mg m-2), another
strongly emetogenic agent, induced acute nausea and emesis paralleled by marked increases in the urinary
excretion of 5-HIAA. Both for high-dose cisplatinum and dacarbazine, the increases in serotonin metabolism
occurred with a similar time-course than those of vomiting, and lasted for a period of 4 to 8 h. Low-dose
cisplatinum (30.8 ±3 mg m-2) as well as cyclophosphamide-based chemotherapies (520±30mgm-2) produced
very small increases in the urinary excretion of 5-HIAA. Platelet and plasma serotonin levels failed to increase
in cyclophosphamide-treated patients. Octreotide, a long-acting somatostatin analog, did not inhibit the
increase in urinary 5-HIAA and the nausea and vomiting produced by high-dose cisplatinum. These results
suggest that for treatments that induce marked increases in serotonin release such as high-dose cisplatinum or
dacarbazine: (a) the amount and time course of serotonin release induced by chemotherapeutic drugs
determines the severity, time of onset and pattern of emesis observed; (b) platelet serotonin play no role in
chemotherapy-induced emesis; (c) strongly emetogenic regimens release serotonin from enterochromaffin cells;
and (d) intestinal release of serotonin is the consequence of the damage induced by the chemotherapeutic
drugs on the gut mucosa.
Nausea and vomiting are serious and frequent complications
of chemotherapeutic drugs (Fetting et al., 1982; Lazlo, 1983;
Martin-Jimenez & Diaz-Rubio, 1985; Gralla et al., 1987). In
addition to marked discomfort, nausea and vomiting affect
patient compliance with subsequent chemotherapy courses
and have been reported to produce physical lesions and fluid
and electrolyte disturbances (Enck, 1977; Lazlo & Lucas,
1981; Martin-Jimenez et al., 1988). In the absence of effective
antiemetic treatment, all patients receiving dacarbazine or
cisplatinum and 60% or more of patients treated with cyclo-
phosphamide-containing regimens experience emesis of
moderate to intense severity (Fetting et al., 1982; Martin-
Jimenez & Diaz-Rubio, 1985; Gralla et al., 1981). It has not
been until recently that some light has been shed on the
mechanisms of vomiting associated to chemotherapeutic
drugs. Serotonin seems to play an important role in the
nausea and vomiting induced by chemotherapeutic agents. In
fact, depletion of tissue serotonin has been shown to abolish
cisplatinum-induced vomiting in laboratory animals (Barnes
et al., 1987) and selective antagonists of serotonin type-3
receptors (5-HT3) reduced the emetic response associated
with chemotherapy, both in animals and human cancer
patients (Leibundgut & Lancranjan, 1987; Cubeddu et al.,
1990a,b; Marty et al., 1990). Further, an increase in the
urinary excretion of 5-hydroxyindole-acetic acid (5-HIAA),
the main metabolite of serotonin, was reported in cancer
patients receiving high doses of cisplatinum (Cubeddu et al.,
1990a). Therefore, it has been proposed that serotonin acting
on 5-HT3 receptors mediates at least part of the nausea and
vomiting induced by chemotherapeutic drugs (Miner &
Sanger, 1986; Costall et al., 1986; Stables et al., 1987).
The present study was conducted to investigate further, in
cancer patients, the mechanisms by which chemotherapeutic
drugs elicits nausea and vomiting. The changes in serotonin
levels and metabolism were evaluated on the first day of the
first cycle of treatment with two strongly emetogenic regi-
mens: high-dose cisplatinum and dacarbazine-based chemo-
therapies, and with two moderately emetogenic treatments:
low-dose cisplatinum and cyclophosphamide-based chemo-
therapies. Specifically, we determined: (a) if serotonin is
released only by high-dose cisplatinum (Cubeddu et al.,
1990a) or could also be released by other commonly employ-
ed chemotherapeutic agents; (b) if there is a relationship
between the amount of serotonin released and the magnitude
of the emetic response to chemotherapeutic drugs, and (c) if
there is a temporal relationship between the release of sero-
tonin and the nausea and vomiting. In addition, the site from
which serotonin is released was investigated by measuring the
plasma-free and platelet concentrations of serotonin and the
plasma-free and urinary excretion of 5-HIAA following
chemotherapy. Finally, the mechanism by which chemothera-
peutic drugs induce serotonin release was assessed by study-
ing the effects of octreotide on serotonin release and
metabolism, in cancer patients receiving high-dose cisp-
latinum. Octreotide, a long-acting somatostatin analog, is a
well known inhibitor of hormonal secretion and inhibits the
release of serotonin from neoplasms of enterochromaffin cells
(Reichlin et al., 1985; Kvols, 1988; Katz & Erstad, 1989).
Methods
Patients
A total of 54 patients with histologically confirmed cancer,
18 years of age or older, who had not received previous
chemotherapeutic drugs, and had a Karnofsky performance
score of at least 60% (Mendelshon, 1987) were enrolled in
the study. Patients were excluded from the study if they had
abnormal liver or renal function tests, or had any nausea and
vomiting within 24 h of the study period. In addition,
patients who received abdominal or pelvic radition therapy
within 48 h prior to or during the 3 days study period were
also excluded from the study. Written informed consent was
obtained from all patients, and the protocols were evaluated
and accepted by the Institutional Review Board at partici-
pating institutions. The study was conducted at the medical
oncology divisions of the Luis Razetti, Padre Machado and
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Domingo Luciani Hospitals of the city of Caracas. A control
group of healthy subjects, that did not receive chemotherapy
was evaluated in an identical manner at the Research Unit of
the Miguel Perez Carreino Hospital.
Chemotherapy and antiemetic treatment
Four types of regimens were studied: high dose cisplatinum
(> 50 mgm-2), low dose cisplatinum (< 40 mgm-2), cyclo-
phosphamide-based (> 500 mgm-2) and dacarbazine- (250-
300 mg m-2) based treatments. Patients received only one of
the strongly emetic regimens. Namely, if they received high-
dose cisplatinum they did not receive dacarbazine and vice
versa. In addition, the cyclophosphamide-based regimens did
not contain cisplatin or dacarbazine. However, the cispla-
tinum or dacarbazine-based chemotherapies could include
cyclophosphamide. Cisplatinum, cyclophosphamide or dacar-
bazine were dissolved in 500 ml of 5% dextrose in 0.45%
sodium chloride and administered at a 60-min intravenous
infusion. The primary agent was followed by administration
of other chemotherapeutic drugs as required for treatment of
the patients' neoplasia. Other chemotherapeutic drugs includ-
ed: methotrexate, doxorubicin, iphosphamide, etoposide, 5-
fluorouracil, mitoxantrone, bleomycin, and/or vincristine.
Patients received any of the following antiemetics pro-
phylactically: metoclopramide (2 mg kg-', i.v. in two or three
doses at 2 h intervals), diphenydramine (50 mg i.v., 10 min
prior to metoclopramide), or ondansetron (0.15 mg kg-' in
three i.v. doses at 4 h intervals). All antiemetics were started
30 min prior to the initiation of the primary chemotherapy
agent. In the event of persisting nausea and/or vomiting, one
or two additional doses of metoclopramide were administer-
ed. Neither ondansetron, dexamethasone or metoclopramide
affect the changes in serotonin metabolism induced by
chemotherapeutic drugs, in cancer patients (Cubeddu et al.,
1990a; Hoffmann & Cubeddu, unpublished observations).
Analytical methods
Plasma andplatelet serotonin
In patients receiving high-dose cisplatinum or cyclophospha-
mide, blood samples were obtained at 30 intervals starting
1 h prior to the chemotherapeutic drug for 4 h; subsequently,
samples were obtained every 2 h for 6 additional hours. The
samples were drawn by venipuncture or through an intra-
venous line, with plastic syringes before and after administra-
tion of the most emetogenic chemotherapeutic drug. Blood
was immediately placed in chilled plastic tubes containing
Na2EDTA 1 mg ml- and sodium metabisulfite 2 mgml1'.
After gentle mixing, blood was centrifuged at 800g for
Omin in a Sorvall Centrifuge (R5) at 4°C. The pellet was
discarded and the supernatant contained the platelet-rich
plasma. A 20 tlI aliquot of the supernatant was diluted in
20 ml of Isopton-2 and the platelet count performed using a
previously calibrated Coulter Thrombo-Counter. A 2 ml sam-
ple of the platelet-rich plasma was centrifuged at 7,000g for
Omin, after additional of dithiotreitol (final concentration
10 1M). The supernatant containing the platelet-free plasma
was treated with perchloric acid (final concentration 0.4 M),
mixed and then centrifuged at 10,000g for 5min to preci-
pitate the proteins. The supernatant containing the free sero-
tonin and 5-HIAA was stored at -40°C until assay (within
1-2 days). The platelet pellet (pellet from 7,000g centrifuga-
tion) was suspended in perchloric acid 0.1 M homogenised
and centrifuged at 10,000g for 5 min. This procedure was
repeated twice. The supernatants were combined, stored at
-440C until assayed for platelet serotonin.
Total serotonin was calculated as follows: platelet sero-
tonin + free serotonin in plasma. Both, platelet and free
serotonin were expressed per ml of plasma. The total plasma
serotonin was obtained from the calculated concentration
of serotonin in plasma times the plasma volume (average
plasma volume for females and males is 40 and 39 ml per
kilogram of body weight, respectively) (taken from Normal
values Appendix of Harrison's Principles of Internal Medi-
cine). The value obtained represented the total amount of
serotonin in plasma, which is similar to the blood content of
serotonin, since no serotonin is present in the RBC.
Urinary excretion of5-HIAA
Urine samples were collected for the determination of 5-
HIAA and creatinine. Samples were collected every 2 h for a
period of 8-12 h, starting 2 h prior to the initation of treat-
ment with the most emetogenic chemotherapeutic drug. This
was followed by a 12-16 h urine sample, to complete the
24 h collection period.
Quantification ofserotonin and5-HIAA
Serotonin and 5-HIAA were quantified by means of high-
performance liquid chromatography with electrochemical
detection (Bioanalytical Systems West Lafayette, Ind.). The
detector potential was maintained at 550 mV in relation to
the value of a silver-silver chloride reference electrode.
Samples for the quantification of platelet serotonin were
diluted 1:5 in 0.1 M perchloric acid. Urine samples were
diluted 1:50 (vol/vol) with 0.1 M perchloric acid, mixed and
centrifuged. All samples were passed through a Millipore
0.45 gm filter, HV, prior to injection into the chromatograph.
A 20 LI loop injection was employed. Separation of com-
pounds was achieved by a Biophase 5-gm, C-18 reversed-
phase column (25 cm by 4 mm internal diameter). The mobile
phase consisted of 0.1 M citric acid, 0.05 M sodium phosphate,
1 mm disodium EDTA, and 17% (vol/vol) methanol (pH4.5).
The sensitivity of the method allowed the detection of 50 pg
of 5-HIAA and 10 pg serotonin. Appropriate adjustments in
the methanol concentration of the mobile phase were made
to achieve optimal separation of compounds and interfering
peaks. Urinary creatinine was measured by a commerically
available colorimetric kit (Direct Creatinine; Bioanalytical
Laboratories, Palm City, Fla).
Statistical analysis
ANOVA and Duncan's multiple rank test were employed to
compare differences between groups. A P values below 0.05
was considered to indicate statistical significance.
Results
Effects ofhigh-dose cisplatinum on the metabolism ofserotonin
in cancerpatients
In this first study, a detailed analysis of the effects of high-
dose cisplatinum on serotonin metabolism was undertaken.
Blood and urine samples for assay were obtained from 16
consecutive cancer hospital inpatients (6M/1OF; mean age
54 ± 6 years) scheduled to receive their first course ofchemo-
therapeutic drugs with high-dose cisplatinum (mean dose:
75±Smgm2).
In the blood samples collected prior to the chemothera-
peutic drugs, nearly 98% of blood serotonin (212 ± 27 ng
ml-' plasma) was found in the platelet-rich plasma fraction;
whereas, free serotonin (present in platelet-free plasma)
averaged 3.2 ± 0.3 nanograms ml-' plasma. The content of
serotonin per platelet averaged 0.33 ng/platelet. The total
amount of serotonin circulating in blood (platelets + free)
was estimated between 0.8 and 1.4 mg. No significant
changes in the content of serotonin per platelet, the number
of platelets or the concentration of serotonin per ml of
plasma were observed in the samples collected over the 10 h
period following cisplatinum administration (Figure 1). Free
serotonin levels showed a tendency to increase from 3 to 7 h
after cisplatinum; however, the changes did not reach statis-
tical significance (Figure 1). On the other hand, there were
larger and sustained increases above baseline in the levels of200 L.X. CUBEDDU et al.
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Figure 1 Effects of high-dose cisplatinum and cyclosphosph-
amide on platelet serotonin and of high-dose cisplatinum on
plasma serotonin and 5-HIAA. Chemotherapy-naive cancer
patients received either cisplatinum (> 50 mg m-2) or cyclophos-
phamide (> 500mg m')-based chemotherapies. Blood samples
were obtained prior to and after cisplatinum or cyclophosph-
amide administration (time zero). a, Effects of cisplatinum and
cyclophosphamide on platelet serotonin. The serotonin levels
were expressed as nanograms of serotonin in platelets per ml of
plasma. b, Effects of cisplatinum on plasma serotonin and 5-
HIAA concentration. Results are expressed in nanograms per ml
of plasma (platelet-free plasma). Significantly different from base-
line at *P<0.05 and **<0.0l.
5-HIAA in plasma and urine following high-dose cisplatinum
(Figures 1 and 2). At 3 and 5 h after cisplatinum 5-HIAA
concentrations doubled those at baseline. Subsequently, the
plasma 5-HIAA levels declined, returning to the baseline
levels 9 h after cisplatinum administration.
The changes in the urinary excretion of 5-HIAA paralleled
those of plasma 5-HIAA (Figures 1 and 2). Increases in
urinary 5-HIAA were observed for the actual rate of excre-
tion (micrograms of 5-HIAA/2 h) (data not shown), as well
as after correcting by urinary creatinine (nanograms 5-
HIAA/microgram creatinine) (Figure 2). The total increase
above baseline levels of 5-HIAA for the 2 to 8 h after
cisplatinum, averaged 1.86 mg. The urinary excretion of 5-
HIAA measured in a control group of healthy volunteers
(3M/3F) showed no significant increases in 5-HIAA, with a
50% decrease in the evening-night (8-24 h) urine sample.
In three patients, the vomiting fluid was assayed for
serotonin; however, no serotonin was detected.
Relationship between the dose ofcisplatinum and the increases
in urinary excretion ofS-HIAA
In a second study, a total of 12 consecutive chemotherapy-
naive patients received either > 50 mg m-2 (high dose; n = 6;
SM/IF; mean age: 54.3 ± 6 years) or <40 mg m 2 (low-dose
cisplatinum; n = 6; 4M/2F; mean age: 51.1 ± 6 years) accord-
ing to the type and stage of their tumours. The average dose
of cisplatinum for the high-dose group was 83.8 ± 5 mg m-2
and for the low-dose group was 30.8 ± 3 mg m 2 (P<0.001).
As shown in the first study, high-dose cisplatinum produced
large increases in the urinary excretion of 5-HIAA (Figure 3).
The sample collected 4-6 h after high-dose cisplatinum
showed 5-HIAA levels that were 3 fold higher than those at
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Figure 2 Effects of chemotherapy with high-dose cisplatinum,
cyclophosphamide or dacarbazine on the urinary excretion of
5-HIAA, in cancer patients. Chemotherapy-naive cancer patients
received treatments based on cisplatinum (>50 mgm-2) (0),
cyclophosphamide (> 500mg m') (A) or dacarbazine (250-300
mg m-2) (0). These agents were administered either alone or in
combination with other anticancer agents. The three main chemo-
therapeutic drug was administered intravenously in 1 h. Urine
samples were obtained prior to and after cisplatinum administra-
tion (time zero). A group of healthy volunteers received a saline
infusion, and was used as controls (0). 5-HIAA excretion was
corrected by creatinine.
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Figure 3 Comparative effects of chemotherapy with low-dose
and high-dose cisplatinum on the urinary excretion of 5-HIAA,
in cancer patients. Chemotherapy-naive cancer patients received
treatments based on low-dose (< 40 mg m') or high-dose cis-
platinum (>50 mg m-2). Cisplatinum was administered intraven-
ously in 1 h. Urine samples were obtained at 2 h intervals prior to
and after cisplatinum administration (time zero). Time zero is the
time in initiation of cisplatinum infusion. Different from baseline
at *P<0.05; **P< .0l.
baseline. There were no significant changes in the urinary
excretion of 5-HIAA in the low-dose cisplatinum group;
however, 6 to 10 h after the chemotherapeutic drugs the
5-HIAA excretion was 60 to 100% higher than at baseline
(Figure 3). The lack of a significant increase in 5-HIAA
excretion may be explained by the fact that only half of the
low-dose cisplatinum patients had an increase in 5-HIAA
excretion; whereas, all patients in the high dose group show-
ed increases in 5-HIAA excretion above baseline.
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Effects ofcyclophosphamide-based and ofdacarbazine-based
chemotherapies on serotonin metabolism
A total of 17 chemotherapy-naive cancer patients (2M/1SF)
received cyclophosphamide (>500mgm-2; mean dose
520 ± 30mgM-2) in combination with either methotrexate
and 5-fluorouracil or doxorubicin and 5-fluorouracil. As for
high-dose cisplatinum, the platelet serotonin content showed
no changes after cyclophosphamide treatment (Figure 1).
Compared to high-dose cisplatinum and dacarbazine (see
below), cyclophosphamide produced a small increase (30%
above baseline) in the urinary excretion of 5-HIAA during
the first 8 h following its administration (Figure 2). However,
the levels of 5-HIAA persisted elevated in the 8 to 24h
urinar sample following treatment with cyclophosphamide;
whereas in the control group, the 5-HIAA/creatinine ratio
decreased from 5.8 ± 1 in the 6-8 h sample to 2.4 ± 0.3 in
the 8-24h sample. A similar magnitude of increase in the
8-24 h excretion of 5-HIAA was observed in the high-dose
cisplatinum, dacarbazine and cyclophosphamide-treated
patients (P>0.1) (Figure 2). The median time to emesis for
cyclophosphamide-treated patients was of 9.4 h.
The effects of 250-300mgm-2 dacarbazine (mean dose:
283 ± 22 mg m-2) on 5-HIAA excretion are shown on Figure
2. A total of five cancer patients (3F/2M; age: 39.6 ± 7 years)
received treatment with dacarbazine in combination with any
of the following: doxorubicin, iphosphamide or cyclophos-
phamide. Dacarbazine induced a marked and rapid increase
in the urinary excretory rate of 5-HIAA. This increase was
similar to that observed with cisplatinum, and paralleled the
rapid onset of nausea and vomiting observed in the dacarb-
azine-treated patients. Despite antiemetic protection (meto-
clopramide + diphenhydramine), the time to the onset of
emesis was 2.5 ± 0.8 h.
Effects ofa somatostatin analog in high-dose
cisplatinum-induced emesis and on 5-HIAA excretion
This experiment was undertaken with purpose of exploring
the mechanism of chemotherapy-induced serotonin release.
Somatostatin is a well known inhibitor of hormonal release
(Katz & Erstad, 1989). The long-acting somatostatin analog,
octreotide (SMS 201-995, Sandostatin), has been shown to
alleviate symptoms, to reduce the release of serotonin and the
levels of 5-HIAA in patients harboring carcinoid tumours
(see Kvols, 1988 for review). The possibility that cisplatinum
induced serotonin release and nausea and vomiting, could be
prevented by pretreatment with octreotide was investigated,
in cancer patients receiving high-dose cisplatinum. The effects
of two different regimens of octreotide were employed: (a)
250 micrograms sc 1 h before and 1 h after cisplatinum, or
(b) at 250 micrograms sc every 8 h the day before and 500
micrograms sc 1 h before and 1 h after cisplatinum. These
treatments failed to prevent the emetic response to cispla-
tinum. In addition, similar increase in the excretion of
urinary 5-HIAA were observed in octreotide-treated patients
than in control patients receiving high-dose cisplatinum
(Table I).
Discussion
In the present study we evaluated the changes in serotonin
and in serotonin metabolism produced by cancer chemo-
therapeutic drugs with the purpose of understanding the
mechanisms by which these agents induce nausea and vomit-
ing. The experiments were conducted in cancer patients
scheduled to receive their first course of chemotherapy.
Chemotherapy-naive patients were selected to avoid the pos-
sible interference of anticipatory emesis, and any effect that
repeated cycles of treatment could have on intestinal sero-
tonin and on serotonin metabolism. The results and discus-
sion were based on the primary chemotherapeutic agent;
however, most patients received treatment with more than
one drug. Consequently, although the changes observed in
Table I Effects of Octreotide on high-dose cisplatinum-induced in-
creases in 5-HIAA excretion
Time after cisplatinum
n 2-4h 4-6h 6-8h 8-24 h
Control 22 118±24 190±25 135±19 39±23
Octeotride 4 79±39 210±40 183±45 22±18
All patients received high-dose cisplatinum (> 50mgm-2) in a 1 h
infusion. Results are shown as percentage of increase above baseline
levels of 5-HIAA excretion (ug of 5-HIAAmg-I of creatinine) at
different times aftercisplatinum. Baseline 5-HIAA/creatinine excretion
averaged: 7.0±0.6 for controls and 5.8±1.3 for octeotride (P>0.1).
serotonin metabolism and the vomiting could be due to the
primary agent, the contribution of other agents cannot be
ruled out. However, in our design, the emetogenic activity of
the associated drugs was less than that of the primary agent.
The observation that depletion of serotonin prevents
cisplatinum-induced vomiting (Barnes et al., 1987), and that
antagonists of serotonin-type 3 receptors are effective against
radiation- and chemotherapy-induced emesis (Miner &
Sanger, 1986; Costall et al., 1986; Smith et al., 1986; Stables
et al., 1987; Fozard, 1987; Andrews et al., 1988; Hawthorn et
al., 1988; Cubeddu et al., 1990a), suggests that serotonin
plays a critical role in the emetic response to these treat-
ments. The present study provides further evident of the role
of serotonin in chemotherapy-induced nausea and vomiting.
First, two strongly emetogenic cytotoxic drugs, high-dose
cisplatinum and dacarbazine, induced marked increases in
the metabolism of serotonin in a time course that paralleled
the onset of nausea and vomiting. Both high-dose cis-
platinum and dacarbazine induce an early (2-3 h after
chemotherapy) and intense emetic response of 4 to 6 h dura-
tion (Martin-Jimenez y Diaz-Rubio, 1985; Gralla et al., 1981;
Cubeddu et al., 1990a; present study). For high-dose cispla-
tinum and for dacarbazine, the comparable time courses for
emesis and for the increase in serotonin metabolism suggests
a cause-effect relationship between serotonin and the emetic
response. Second, two chemotherapeutic drugs with mild to
moderate emetic activity, cyclophosphamide and low-dose
cisplatinum, produced smaller and less consistent increases in
serotonin metabolism than the strongly emetogenic cytotox-
ics; therefore, a temporal relationship between the emetic
response and the urinary excretion of 5-HIAA could not be
determined for these two treatments. Contrary to cisplatinum
and dacarbazine, cyclophosphamide does not produce early
emesis (Fetting et al., 1982; Cubeddu et al., 1990b), nor does
it produce an early increase in 5-HIAA (present study). The
results of this study suggest that the amount of serotonin
released and the time course of the release determines the
severity, the time of onset and the pattern of emesis induced
by a specific chemotherapeutic drug. If a cytotoxic drug
induces a large release of serotonin within a short period of
time, an intense period of vomiting would be expected for
this drug, associated to large increases in urinary excretion
rate of 5-HIAA. However, if lower amounts of serotonin are
released or even if the total amount of serotonin released is
similar to that produced by high-dose cisplatinum, but the
release occurs over a long period of time (i.e., 24 h), only
mild to moderate vomiting spread out over the time of
serotonin release would develop. In addition, significant inc-
reases above baseline in urinary 5-HIAA excretion may not
be observed since the amount of serotonin released will be
diluted over many hours.
Information about the source of serotonin released by
chemotherapeutic drugs can be obtained from data on the
normal distribution of serotonin in the body. In humans,
nearly 80% of the serotonin is in the gastrointestinal tract
(6-9 mg), 95% of which is within enterochromaffin, as well
as in other enteroendocrine cells. The rest of the body sero-
tonin is divided between platelets (1-2mg), and other tis-
sues, including the CNS (1 mg) (Feldberg & Toh, 1953;
Ersparmer, 1954; Resnick & Gray, 1961). High-dose cispla-202 L.X. CUBEDDU et al.
tinum and dacarbazine releases approximately 1 to 3 mg of
serotonin over a period of 6 h. Thus, if serotonin were to be
released from platelets, a complete emptying of all serotonin
platelet content would be required in order to account for the
changes in 5-HIAA observed after high-dose cisplatinum or
dacarbazine. However, in the present study we demonstrated
that neither high-dose cisplatinum, nor cyclophosphamide
affect the platelet serotonin content. Consequently, the most
likely source of the increase in 5-HIAA is the enterochrom-
affin and enteroendocrine cells of the gastrointestinal tract.
These findings support previous observations indicating that
urinary 5-HIAA is a marker of gastrointestinal serotonin
content and turnover (Ersparmer & Testini, 1959; Bertaccini,
1960). Therefore, an increase in urinary 5-HIAA excretion (in
the absence of carcinoid tumoral cells) should reflect in-
creases in turnover (increase synthesis and/or release) of
gastrointestinal serotonin. Interestingly, in ferrets, cispla-
tinum increases the gastrointestinal turnover of serotonin
(Gunning et al., 1987). In summary, these findings suggest
that high-dose cisplatinum and dacarbazine, and probably
cyclophosphamide, release serotonin from the enterochrom-
affin cells of the gastrointestinal tract.
Once released, serotonin could act locally or pass into the
circulation in order to induce nausea and vomiting. The
contribution of plasma serotonin was explored in this inves-
tigation. However, neither platelet serotonin nor free plasma
serotonin increased significantly during the period of intense
emesis after high-dose cisplatinum, suggesting that most of
the serotonin released from enterochromaffin cells is con-
verted to 5-HIAA within the gut wall and/or is released from
the gut into the portal system and converted to 5-HIAA on
its passage through the liver (a first pass extraction has been
demonstrated for serotonin). These results suggest that it is
the free serotonin within the gut wall and not the circulating
serotonin that plays an active role in emesis induced by
chemotherapeutic drugs. This is consistent with the clinical
observation that patients with carcinoid tumours may have
very high concentrations serotonin in plasma, yet do not
experience the intense emesis observed in cisplatinum or
dacarbazine-treated patients (Martin-Jimenez & Diaz-Rubio,
1985; Kvols, 1988). In favour of a local, intestinal site of
action for serotonin, is the observation that visceral denerva-
tion of the ferret, prevents cisplatinum-induced vomiting in
this animal (Hawthorn et al., 1988).
Presently, the mechanism by which chemotherapeutic
agents induce the release of serotonin is unknown. The
presence of receptors on enterochromaffin and in enteroendo-
crine cells for each of the cytotoxics is unlikely, rather a
mechanism related to their cytotoxicity is more plausible. The
drugs with strongest emetic activity act as aklylating agents,
inhibit DNA biosynthesis and kill cells in all stages of the cell
cycle. Rapid cell killing may release substances from dying
cells that induce serotonin release from enteric serotonin-
containing cells, the cytotoxics may have a specific direct
damaging effect on the serotonin cells and/or produce severe
mucosal damage and an unspecific damage of the serotonin-
containing cells leading to serotonin release. If the release
occurs through a normal secretory process, it would be sen-
sitive to somatostatin, a well known inhibitor of hormonal
secretion (Katz & Erstad, 1989; Reichlin, 1985) and of sero-
tonin release from carcinoid tumours, which are neoplasms
of enterochromaffin cells (Kvols, 1988). Octreotide, a stable
long-acting analog of the peptide hormone somatostatin,
reduces clinical symptoms, inhibits serotonin release and
decreases urinary levels of 5-HIAA in carcinoid patients (see
Kvols, 1988 for review). However, with the two treatment
schedules employed the somatostatin analog failed to prevent
both the emetic response as well as the increases in 5-HIAA
induced by high-dose cisplatinum in cancer patients (present
study). These results suggest that cisplatinum in high doses
induces serotonin release by a mechanism different of the
normal secretory hormonal release, and of that observed in
tumoral enterochromaffin cells. Studies in experimental
animals revealed a severe mucosal damage of the ileum and
jejunum after high-dose cisplatinum, and that the extent of
the damage was related to the severity of emesis (Gunning et
al., 1987). Consequently, although the precise mechanism of
cytotoxic-induced gastrointestinal serotonin release is unclear,
it seems to be through a direct or indirect lesion of the
enterochromaffin cells.
In summary, the serotonin hypothesis could be stated as
follows: 'chemotherapeutic drugs and radiotherapy induces
the release of serotonin from enterochromaffin and/or other
enteroendocrine cells perhaps by damage of the gut mucosa,
the released serotonin would activate 5-HT3 receptors on
visceral afferent fibres increasing afferent input to the brain,
stimulating the chemoreceptor trigger zone and/or vomiting
centre with the consequent production of nausea and emesis.
The serotonin released would be metabolised within the intes-
tine and/or on its passage through the liver, leading to
increases both in plasma and urine of its main metabolite,
5-HIAA. The changes in 5-HIAA would reflect the amount
of serotonin released and the severity and pattern of the
emetic response'. From a teleological point of view, chemo-
therapeutic drugs or radiotherapy-produced emesis, may re-
present an old-learned, life-saving reflex to eliminate ingested
toxins that damage the gastrointestinal mucosa. The reflex is
triggered even ifdrugs or agents that damage the gut mucosa
are administered by routs other than the oral, such as in the
case of chemotherapeutic agents and irradiation therapy.
Although we have oriented our discussion in favour of a
peripheral mechanism for serotonin-induced emesis, there is
strong evidence in favour of a central site of action for
serotonin and serotonin antagonists. For example, central
administration of cisplatinum has been reported to induce
vomiting in dogs (Smith et al., 1988) and the central adminis-
tration of 5-HT3 antagonists prevents vomiting induced by
cisplatinum (Higgins et al., 1989). The largest concentration
of 5-HT3 receptors is present in the brain medulla in the
nucleus tractus solitarious and area postrema regions, where
the chemoreceptor trigger zone is located and where the
vagal afferents enter the brain (Kilpatrick et al., 1989). On
this line, we may add that patients receiving low doses of
cisplatinum or cyclphosphamide-based treatments showed
either small or no increases in urinary 5-HIAA excretion,
nevertheless they experienced mild to moderate emesis, and
their emesis was controlled by 5-HT3 antagonists (Cubeddu
et al., 1990b). One possibility is that measurements ofurinary
5-HIAA may not be sensitive enough to detect small in-
creases in serotonin release induced by cytotoxics with mild
to moderate emetic activity. However, it is also possible that
the nausea and vomiting associated to low-dose cisplatinum
and cyclophosphamide-based treatments, is mediated mainly
through central mechanisms; whereas that induced by high-
dose cisplatinum and dacarbazine may be triggered by peri-
pheral as well as by central mechanisms. Thus, serotonin and
5-HT3 receptors play a role both at the periphery as well as
in the CNS, and the relative contribution of peripheral and
central sites may vary with the type of cytotoxic agent
employed, its dose and mechanism of action.
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